PATENT CLAIM ANALYSIS

Application Number: 16066072
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "377000"]

Abstract:
The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of chemotherapy-induced neuropathy, preferably in the treatment and/or prevention of chemotherapy-induced peripheral neuropathy (CIPN) or chemotherapy-induced optic neuropathy.

Claim (Index 48):
The method according to  claim 47 , wherein the taxane is Paclitaxel and the platinum based drug is oxaliplatin.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 94.0
- Lexical Diversity: 1.43333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14242574', '15170335', '11587937', '13420111', '15066416']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7904118774877831
- 35 USC 102 Novelty (BERT): 0.521692489264524
- Combined Prediction Score: 0.7635399386654571
- Mean Citation Score: 275.75967799999995
- Max Citation Score: 284.75754
- Similarity Product: 163.11863518041372

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test